FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153558008> ?p ?o ?g. }

• W2153558008 endingPage "4957" @default.
• W2153558008 startingPage "4952" @default.
• W2153558008 abstract "Purpose The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy. Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL). We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL. Patients and Methods Patients were treated with oral lenalidomide 25 mg once daily on days 1 to 21, every 28 days, for 52 weeks, until disease progression or intolerance. The primary end point was response; secondary end points included duration of response, progression-free survival (PFS), and safety. Results Forty-nine patients with a median age of 65 years received lenalidomide in this study. The most common histology was diffuse large B-cell lymphoma (53%), and patients had received a median of four prior treatment regimens for NHL. An objective response rate of 35% was observed in 49 treated patients, including a 12% rate of complete response/unconfirmed complete response. Responses were observed in each aggressive histologic subtype tested (diffuse large B-cell, follicular center grade 3, mantle cell, and transformed lymphomas). Of patients with stable disease or partial response at first assessment, 25% improved with continued treatment. Estimated median duration of response was 6.2 months, and median PFS was 4.0 months. The most common grade 4 adverse events were neutropenia (8.2%) and thrombocytopenia (8.2%); the most common grade 3 adverse events were neutropenia (24.5%), leukopenia (14.3%), and thrombocytopenia (12.2%). Conclusion Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects." @default.
• W2153558008 created "2016-06-24" @default.
• W2153558008 creator A5007237464 @default.
• W2153558008 creator A5015136036 @default.
• W2153558008 creator A5025688165 @default.
• W2153558008 creator A5045079164 @default.
• W2153558008 creator A5046116136 @default.
• W2153558008 creator A5049069261 @default.
• W2153558008 creator A5049662208 @default.
• W2153558008 creator A5055075571 @default.
• W2153558008 creator A5055986048 @default.
• W2153558008 creator A5065587495 @default.
• W2153558008 creator A5080373697 @default.
• W2153558008 creator A5082462119 @default.
• W2153558008 creator A5089619585 @default.
• W2153558008 creator A5091651670 @default.
• W2153558008 date "2008-10-20" @default.
• W2153558008 modified "2023-10-07" @default.
• W2153558008 title "Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma" @default.
• W2153558008 cites W1597238753 @default.
• W2153558008 cites W1822166136 @default.
• W2153558008 cites W1912693401 @default.
• W2153558008 cites W1973532909 @default.
• W2153558008 cites W1983330474 @default.
• W2153558008 cites W2030646758 @default.
• W2153558008 cites W2041879310 @default.
• W2153558008 cites W2049869153 @default.
• W2153558008 cites W2058015212 @default.
• W2153558008 cites W2066936999 @default.
• W2153558008 cites W2073886406 @default.
• W2153558008 cites W2083831464 @default.
• W2153558008 cites W2119680582 @default.
• W2153558008 cites W2120775216 @default.
• W2153558008 cites W2133986577 @default.
• W2153558008 cites W2144531125 @default.
• W2153558008 cites W2153665789 @default.
• W2153558008 cites W2167571754 @default.
• W2153558008 cites W2253342312 @default.
• W2153558008 cites W2263260431 @default.
• W2153558008 cites W2264834016 @default.
• W2153558008 cites W2313423582 @default.
• W2153558008 doi "https://doi.org/10.1200/jco.2007.15.3429" @default.
• W2153558008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18606983" @default.
• W2153558008 hasPublicationYear "2008" @default.
• W2153558008 type Work @default.
• W2153558008 sameAs 2153558008 @default.
• W2153558008 citedByCount "350" @default.
• W2153558008 countsByYear W21535580082012 @default.
• W2153558008 countsByYear W21535580082013 @default.
• W2153558008 countsByYear W21535580082014 @default.
• W2153558008 countsByYear W21535580082015 @default.
• W2153558008 countsByYear W21535580082016 @default.
• W2153558008 countsByYear W21535580082017 @default.
• W2153558008 countsByYear W21535580082018 @default.
• W2153558008 countsByYear W21535580082019 @default.
• W2153558008 countsByYear W21535580082020 @default.
• W2153558008 countsByYear W21535580082021 @default.
• W2153558008 countsByYear W21535580082022 @default.
• W2153558008 countsByYear W21535580082023 @default.
• W2153558008 crossrefType "journal-article" @default.
• W2153558008 hasAuthorship W2153558008A5007237464 @default.
• W2153558008 hasAuthorship W2153558008A5015136036 @default.
• W2153558008 hasAuthorship W2153558008A5025688165 @default.
• W2153558008 hasAuthorship W2153558008A5045079164 @default.
• W2153558008 hasAuthorship W2153558008A5046116136 @default.
• W2153558008 hasAuthorship W2153558008A5049069261 @default.
• W2153558008 hasAuthorship W2153558008A5049662208 @default.
• W2153558008 hasAuthorship W2153558008A5055075571 @default.
• W2153558008 hasAuthorship W2153558008A5055986048 @default.
• W2153558008 hasAuthorship W2153558008A5065587495 @default.
• W2153558008 hasAuthorship W2153558008A5080373697 @default.
• W2153558008 hasAuthorship W2153558008A5082462119 @default.
• W2153558008 hasAuthorship W2153558008A5089619585 @default.
• W2153558008 hasAuthorship W2153558008A5091651670 @default.
• W2153558008 hasConcept C126322002 @default.
• W2153558008 hasConcept C141071460 @default.
• W2153558008 hasConcept C143998085 @default.
• W2153558008 hasConcept C197934379 @default.
• W2153558008 hasConcept C203092338 @default.
• W2153558008 hasConcept C2776063141 @default.
• W2153558008 hasConcept C2776364478 @default.
• W2153558008 hasConcept C2776694085 @default.
• W2153558008 hasConcept C2777058707 @default.
• W2153558008 hasConcept C2777063308 @default.
• W2153558008 hasConcept C2777525834 @default.
• W2153558008 hasConcept C2778476748 @default.
• W2153558008 hasConcept C2778850193 @default.
• W2153558008 hasConcept C2779338263 @default.
• W2153558008 hasConcept C2780873365 @default.
• W2153558008 hasConcept C535046627 @default.
• W2153558008 hasConcept C71924100 @default.
• W2153558008 hasConcept C90924648 @default.
• W2153558008 hasConceptScore W2153558008C126322002 @default.
• W2153558008 hasConceptScore W2153558008C141071460 @default.
• W2153558008 hasConceptScore W2153558008C143998085 @default.
• W2153558008 hasConceptScore W2153558008C197934379 @default.
• W2153558008 hasConceptScore W2153558008C203092338 @default.
• W2153558008 hasConceptScore W2153558008C2776063141 @default.

• next